Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status.
Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status.
复制标题
DOI：
10.3390/medicina57111273
复制
发表时间：
2021-11-19
期刊：
影响因子：
--
通讯作者：
Kagamu H
中科院分区：
文献类型：
--
作者：
Kaira K;Imai H;Mouri A;Yamaguchi O;Kagamu H
免疫检查点抑制剂(ICIS)是肺癌患者的标准治疗方法。选择PD-1/PD-L1或CTLA4抗体作为一线治疗，有助于患者的长期存活和耐受性。与分子靶向药物不同，如吉非替尼，表现状态(PS)较差的肺癌患者在ICI治疗后临床改善不令人满意。先前的几个报告也表明PS被认为是预测ICI治疗后不良结果的最可能的预后因素之一。然而，如果PD-L1表达大于50%，一线培溴利珠单抗似乎对PS为2的肺癌患者有效。目前，PS水平较低的肺癌患者ICIS的诱导仍存在争议。本文对这些问题进行了讨论。
Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability. Unlike molecular targeting agents, such as gefitinib, lung cancer patients with a poor performance status (PS) display unsatisfactory clinical improvements after ICI treatment. Several previous reports also demonstrated that the PS is identified as one of the most probable prognostic factors for predicting poor outcomes after ICI treatment. However, first-line pembrolizumab seemed to be effective for lung cancer patients with a PS of 2 if PD-L1 expression was greater than 50%. Currently, the induction of ICIs in patients with lung cancer with a poor PS is controversial. These problems are discussed in this review.
登录
查看更多内容
影响因子：
3.9
作者：
Katsura, Hideyuki;Suga, Yukio;Mase, Hiroki
通讯作者：
Mase, Hiroki
影响因子：
10.9
作者：
Ouaknine Krief, Julia;Helly de Tauriers, Pierre;Giroux Leprieur, Etienne
通讯作者：
Giroux Leprieur, Etienne
DOI：
10.1016/s1470-2045(18)30078-0
发表时间：
2018-03
期刊：
The Lancet. Oncology
影响因子：
--
作者：
McQuade JL;Daniel CR;Hess KR;Mak C;Wang DY;Rai RR;Park JJ;Haydu LE;Spencer C;Wongchenko M;Lane S;Lee DY;Kaper M;McKean M;Beckermann KE;Rubinstein SM;Rooney I;Musib L;Budha N;Hsu J;Nowicki TS;Avila A;Haas T;Puligandla M;Lee S;Fang S;Wargo JA;Gershenwald JE;Lee JE;Hwu P;Chapman PB;Sosman JA;Schadendorf D;Grob JJ;Flaherty KT;Walker D;Yan Y;McKenna E;Legos JJ;Carlino MS;Ribas A;Kirkwood JM;Long GV;Johnson DB;Menzies AM;Davies MA
通讯作者：
Davies MA
影响因子：
10.9
作者：
Alessi, Joao, V;Ricciuti, Biagio;Awad, Mark
通讯作者：
Awad, Mark
影响因子：
5.3
作者：
Fujimoto, Daichi;Yoshioka, Hiroshige;Hirai, Toyohiro
通讯作者：
Hirai, Toyohiro